Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
Authors:
Open Access
- 3 June 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 14 (6) , 2220-2230
Abstract
Milademetan is a small‐molecule inhibitor of murine double minute 2 (MDM2) that is in clinical development for advanced solid tumors and hematological cancers, including liposarcoma and acute myeloid leukemia. Milademetan is a CYP3A and P‐glycoprotein substrate and moderate CYP3A inhibitor. The current study aims to understand the drug‐drug interaction (DDI) risk of milademetan as a CYP3A substrate during its early clinical development. A clinical DDI study of milademetan (NCT03614455) showed that concomitant administration of single‐dose milademetan with the strong CYP3A inhibitor itraconazole or posaconazole increased milademetan mean area under the curve from zero to infinity (AUCinf) by 2.15‐fold (90% confidence interval [CI], 1.98–2.34) and 2.49‐fold (90% CI, 2.26–2.74), respectively, supporting that the milademetan dose should be reduced by 50% when concomitantly administered with strong CYP3A inhibitors. A physiologically‐based pharmacokinetic (PBPK) model of milademetan was subsequently developed to predict the magnitude of CYP3A‐mediated DDI potential of milademetan with moderate CYP3A inhibitors. The PBPK model predicted an increase in milademetan exposure of 1.72‐fold (90% CI, 1.69–1.76) with fluconazole, 1.91‐fold (90% CI, 1.83–1.99) with erythromycin, and 2.02‐fold (90% CI, 1.93–2.11) with verapamil. In addition, it estimated that milademetan’s original dose (160 mg once daily) could be resumed from its half‐reduced dose 3 days after discontinuation of concomitant strong CYP3A inhibitors. The established PBPK model of milademetan was qualified and considered to be robust enough to support continued development of milademetan.Keywords
This publication has 15 references indexed in Scilit:
- Model‐Based Assessments of CYP‐Mediated Drug–Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical DevelopmentClinical Pharmacology & Therapeutics, 2017
- What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015Drug Metabolism and Disposition, 2017
- Physiologically based pharmacokinetic modeling in regulatory decision‐making at the European Medicines AgencyClinical Pharmacology & Therapeutics, 2016
- Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory AcceptanceCurrent Pharmacology Reports, 2016
- Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approachExpert Review of Clinical Pharmacology, 2013
- Physiologically-Based Pharmacokinetics in Drug Development and Regulatory ScienceAnnual Review of Pharmacology and Toxicology, 2011
- Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of InteractionDrug Metabolism and Disposition, 2009
- Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 In VivoClinical Pharmacology & Therapeutics, 2007
- ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITIONDrug Metabolism and Disposition, 2004
- Itraconazole Decreases Renal Clearance of DigoxinTherapeutic Drug Monitoring, 1997